Radiological Society of North America , Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease .

More: continued here